Our Technologies and Organization

News and Updates

Rubicon to Exhibit at BIO 2017

Tags : 

Lake Forest, CA (June 14th, 2017) –  Rubicon Biotechnology has been selected to exhibit and showcase your technology at the upcoming Biotechnology Innovation Organization (BIO), this year in San Diego, CA June 19-22, 2017. Rubicon was invited as part of a SBIR/STTR program which has funded many promising technologies and is committed to assisting its grantees/awardees.

Read More

Welcome to Rubicon Biotechnology

Tags : 

Rubicon Biotechnology LLC is a drug development company located in Orange County, California.  Rubicon’s mission is to develop targeted therapies that will provide substantial and practical benefit to the patient. We are developing two novel technology platforms: Fv-Hsp70 and Modified Annexin.

Read More

Rubicon Signs Agreement with Foothill Scientific

Tags : 

Lake Forest, CA  (January 25th, 2017) – Rubicon Biotechnology and Foothill Scientific Associates (FSA) announce an agreement in which Rubicon will contract with Foothill Scientific Associates for services related to government grants, contracting, product development and business development.

Read More

Rubicon to Present at the 2016 BioInvestor Forum

Tags : 

Lake Forest, CA (October 12th, 2016) – Richard Richieri, COO of Rubicon Biotechnology, will be presenting at the BioInvestor Forum in San Francisco, CA on Oct 18th, 2016. The presentation titled “Developing a Treatment for Heart Attack Victims” will showcase Rubicon’s development of our novel Fv-Hsp70 protein.

Read More

Rubicon Announces Heat Shock Protein Publication

Tags : 

Lake Forest, CA (September 16, 2016) –  Rubicon Biotechnology, LLC announces the publication of a review article called “Targeted Heat Shock Protein 72 for Cytoprotection” by Dr. Missag Parseghian, Chief Scientific Officer of Rubicon, in the Annals of the New York Academy of Sciences.

Read More

Fv-Hsp70 Shows Efficacy in Myocardial Infarction

Tags : 

Lake Forest, CA (November 10, 2015) – Rubicon Biotechnology, LLC is pleased to announce the results showing a statistically significant reduction in infarct volume in an animal myocardial infarction model will be presented at the American Heart Association’s annual Scientific Sessions conference in Orlando, FL.

Read More

Rubicon Awarded NCI Breast Cancer Grant

Tags : 

Lake Forest, CA (August 17th, 2015) – Rubicon Biotechnology, LLC is pleased to announce that it was awarded a SBIR Phase I grant by the National Cancer Institute to study Annexin A5 fusion proteins in two pre-clinical breast cancer models. In this grant, Rubicon will conjugate an Annexin A5 variant to candidate effector molecules.

Read More

Rubicon Signs Agreement for Modified Annexin

Tags : 

    Lake Forest, CA (July 7, 2015) – Rubicon Biotechnology, LLC (www.rubiconbio.com) is pleased to announce that it has entered into an agreement with MosaMedix B.V. to acquire the exclusive worldwide license for an engineered variant of Annexin A5, a natural protein that directly binds to phosphatidylserine (PS) with high affinity.

Read More

Rubicon Signs Exclusive License for Fv-Hsp70

Tags : 

Lake Forest, CA (June 8, 2015) – Rubicon Biotechnology announced today that it has entered into an exclusive license agreement with the Department of Veterans Affairs (VA) to practice U.S. Patent Application Serial No. 13/815,829 (Antibody Mediated Transduction of Heat Shock Proteins into Living Cells). 

Read More

Rubicon to Present at the 9th Annual CounterACT Meeting

Tags : 

Lake Forest, CA (June 5th, 2015) – Dr. Missag Parseghian, CSO of Rubicon Biotechnology, will be presenting at the 9th Annual Countermeasures Against Chemical Threats (CounterACT) Network Research Symposium meeting in New York City on June 12th, 2015. The event will take place on June 15–17, 2015.

Read More

Rubicon Awarded Phase I SBIR Grant from NHLBI

Tags : 

Lake Forest, CA (July 28th, 2014) – Rubicon Biotechnology, LLC is pleased to announce that it was awarded a Phase I grant by the NHLBI to study Fv-Hsp70 as a cytoprotectant in a myocardial infarction model. Rubicon’s grant is titled “Intracellular targeting Hsp70 for myocardial cytoprotection after an infarction”.

Read More

Rubicon to Present at the 8th Annual CounterACT Meeting

Tags : 

Lake Forest, CA (June 12th, 2014) – Dr. Missag Parseghian, CSO of Rubicon Biotechnology, will be presenting at the 2014 CounterACT meeting in Denver CO on June 17th, 2014. The poster and oral presentation is titled “Intracellular Targeting of Hsp70 for Pulmonary Cytoprotection after Phosgene Inhalation“.

Read More

Rubicon Awarded Multi-Year CounterACT Grant

Tags : 

Lake Forest, CA (January 27th, 2014) – Rubicon Biotechnology, LLC is pleased to announce that it was awarded a two year $619,000 CounterACT grant by the NIH to study Fv-Hsp70 as a cytoprotectant against inhaled toxins. Rubicon’s grant is titled “Intracellular targeting Hsp70 for pulmonary cytoprotection after toxin inhalation”.

Read More

Developing novel bio-therapeutics for substantial and practical impact